CLDX, US15117B2025

Celldex Therapeutics stock fell 4.84 percent to USD 27.53 on October 16, 2026

Published on 10/17/2026 at 21:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

USD 61.92 was the target on October 9, 2026. Celldex Therapeutics stock cost USD 27.53 on October 16, 2026, down 4.84 percent versus Nasdaq close.

Trading dates and valuation

Celldex Therapeutics fell in Nasdaq trading on October 16, 2026.
MarketBeat cited a USD 61.92 average target from 14 analysts on October 9, 2026.
Celldex Therapeutics stock cost USD 27.53 at Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 4.84 percent versus the Nasdaq prior close of USD 28.93.
Celldex Therapeutics is estimated to report third-quarter results on November 9, 2026.

CLDX, US15117B2025, Illustration mit AI erstellt.

Celldex Therapeutics (ISIN US15117B2025) fell 4.84 percent in the Nasdaq session on October 16, 2026. The move places the stock at USD 27.53, below its 52-week high of USD 45.14 and above its 52-week low of USD 22.10. Celldex Therapeutics closed at USD 27.53 on October 16, 2026 at 4:00 p.m. ET.

The target remains far above the price

MarketBeat cited an average 12-month target of USD 61.92 from 14 analysts on October 9, 2026. The target is stated in US dollars, the currency of the Nasdaq listing, and is not combined with the Nasdaq closing price as a single return measure.

Range and volume set the frame

Celldex traded between USD 27.47 and USD 28.89 on October 16, 2026, while volume reached 997,947 shares against an average of 1.09 million. The closing price stood 38.99 percent below the 52-week high of USD 45.14 and 24.57 percent above the low of USD 22.10. The stock was up 1.50 percent from its start-of-year level of USD 27.16.

The Nasdaq listing is identified as NASDAQ:CLDX by MarketBeat. Celldex is a clinical-stage biotechnology company developing antibody-based therapies, with barzolvolimab among its lead candidates. The company has 198 full-time employees.

Results date brings the next test

MarketBeat estimates that Celldex will report third-quarter 2026 results on November 9, 2026, after the market closes. The conference call is scheduled for November 2, 2026 at 4:00 p.m. ET. The same source lists a consensus estimate of a USD 1.02 loss per share and USD 0.72 million in revenue for the quarter.

Comparison with peers

Celldex Therapeutics (Nasdaq, USD): minus 4.84 percent, market capitalization USD 2.2 billion
Immunic (Nasdaq, USD): minus 1.83 percent, market capitalization USD 95.1 million
Viking Therapeutics (Nasdaq, USD): minus 8.04 percent, market capitalization USD 3.2 billion

Price closes below the yearly high

Celldex ended the October 16, 2026 Nasdaq session at USD 27.53 at 4:00 p.m. ET, down 4.84 percent from the Nasdaq prior close of USD 28.93. The closing level is 38.99 percent below the 52-week high and 24.57 percent above the 52-week low.